Beyond the Valve and into the Muscle: A Review of Coexisting Aortic Stenosis and Transthyretin Cardiac Amyloidosis

References

• Nishimura RA, Otto CM, Bonow RO, et al. AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;63:2438–2488. doi:10.1016/j.jacc.2014.02.537.
   PubMed Web of Science ®Google Scholar
• Bavishi C, Balasundaram K, Argulian E. Integration of flow-gradient patterns into clinical decision making for patients with suspected severe aortic stenosis and preserved LVEF: a systematic review of evidence and meta-analysis. JACC Cardiovasc Imaging. 2016;9:1255–1263. doi:10.1016/j.jcmg.2016.01.035.
   PubMed Web of Science ®Google Scholar
• Pibarot P, Dumesnil JG. Paradoxical low-flow, low-gradient aortic stenosis: new evidence, more questions. Circulation. 2013;128:1729–1732. doi:10.1161/CIRCULATIONAHA.113.005718.
   Web of Science ®Google Scholar
• Connors LH, Sam F, Skinner M, et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study. Circulation. 2016;133:282–290. doi:10.1161/CIRCULATIONAHA.115.018852.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36:2585–2594. doi:10.1093/eurheartj/ehv338.
   PubMed Web of Science ®Google Scholar
• Nietlispach F, Webb JG, Ye J, et al. Pathology of transcatheter valve therapy. JACC Cardiovasc Interv. 2012;5:582–590. doi:10.1016/j.jcin.2012.03.012.
   PubMed Web of Science ®Google Scholar
• Solomon SD, Adams D, Kristen A, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation. 2019;139:431–443. doi:10.1161/CIRCULATIONAHA.118.035831.
   PubMed Web of Science ®Google Scholar
• Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:22–31. doi:10.1056/NEJMoa1716793.
   PubMed Web of Science ®Google Scholar
• Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11–21. doi:10.1056/NEJMoa1716153.
   PubMed Web of Science ®Google Scholar
• Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007–1016. doi:10.1056/NEJMoa1805689.
   PubMed Web of Science ®Google Scholar
• Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. 2017;135:1357–1377. doi:10.1161/CIRCULATIONAHA.116.024438.
   PubMed Web of Science ®Google Scholar
• Treibel TA, Fontana M, Gilbertson JA, et al. Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement. Circ Cardiovasc Imaging. 2016;9(8). doi:10.1161/CIRCIMAGING.116.005066.
   Web of Science ®Google Scholar
• Galat A, Guellich A, Bodez D, et al. Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg? Eur Heart J. 2016;37:3525–3531. doi:10.1093/eurheartj/ehw033.
   PubMed Web of Science ®Google Scholar
• Castano A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38:2879–2887. doi:10.1093/eurheartj/ehx350.
   PubMed Web of Science ®Google Scholar
• Kristen AV, Schnabel PA, Winter B, et al. High prevalence of amyloid in 150 surgically removed heart valves–a comparison of histological and clinical data reveals a correlation to atheroinflammatory conditions. Cardiovasc Pathol. 2010;19:228–235. doi:10.1016/j.carpath.2009.04.005.
   Web of Science ®Google Scholar
• Hutt DF, Fontana M, Burniston M, et al. Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. Eur Heart J Cardiovasc Imaging. 2017;18:1344–1350. doi:10.1093/ehjci/jew325.
   PubMed Web of Science ®Google Scholar
• Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6:195–201. doi:10.1161/CIRCIMAGING.112.000132.
   PubMed Web of Science ®Google Scholar
• Castano A, Haq M, Narotsky DL, et al. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol. 2016;1:880–889. doi:10.1001/jamacardio.2016.2839.
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133:2404–2412. doi:10.1161/CIRCULATIONAHA.116.021612.
   PubMed Web of Science ®Google Scholar
• Haq M, Pawar S, Berk JL, Miller EJ, Ruberg FL. Can (99m)Tc-Pyrophosphate aid in early detection of cardiac involvement in asymptomatic variant TTR amyloidosis? JACC Cardiovasc Imaging. 2017;10:713–714. doi:10.1016/j.jcmg.2016.06.003.
   Web of Science ®Google Scholar
• Cavalcante JL, Rijal S, Abdelkarim I, et al. Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis. J Cardiovasc Magn Reson. 2017;19(1):98. doi:10.1186/s12968-017-0415-x.
   Web of Science ®Google Scholar
• Scully PR, Treibel TA, Fontana M, et al. Prevalence of cardiac amyloidosis in patients referred for transcatheter aortic valve replacement. J Am Coll Cardiol. 2018;71:463–464. doi:10.1016/j.jacc.2017.11.037.
   PubMed Web of Science ®Google Scholar
• Sperry BW, Jones BM, Vranian MN, Hanna M, Jaber WA. Recognizing transthyretin cardiac amyloidosis in patients with aortic stenosis: impact on prognosis. JACC Cardiovasc Imaging. 2016;9:904–906. doi:10.1016/j.jcmg.2015.10.023.
   Web of Science ®Google Scholar
• Longhi S, Lorenzini M, Gagliardi C, et al. Coexistence of degenerative aortic stenosis and wild-type transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging. 2016;9:325–327. doi:10.1016/j.jcmg.2015.04.012.
   PubMed Web of Science ®Google Scholar
• Grogan M, Scott CG, Kyle RA, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68:1014–1020. doi:10.1016/j.jacc.2016.06.033.
   PubMed Web of Science ®Google Scholar
• Vyndaqel (tafamidis Meglumine) [package insert]. New York, NY: Pfizer Labs; 2019.
   Google Scholar
• Tegsedi (inotersen) [package insert]. Boston, MA: Akcea Therapuetics, Inc; 2018.
   Google Scholar
• Maurer MS, Heitner S, Drachman B, et al. Inotersen improves quality of life in patients with herediatry transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study neuro-TTR. J Am Coll Cardiol. 2018;71(Supplement). doi:10.1016/S0735-1097(18)31199-9.
   Google Scholar
• Onpattro (patisaran) [package insert]. Cambridge, MA: Alnylam Phamaceuticals, Inc; 2018.
   Google Scholar
• Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369:819–829. doi:10.1056/NEJMoa1208760.
   PubMed Web of Science ®Google Scholar
• Suhr OB, Coelho T, Buades J, et al. Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet J Rare Dis. 2015;10:109. doi:10.1186/s13023-015-0326-6.
   PubMed Web of Science ®Google Scholar
• Minamisawa M, Claggett B, Adams D, et al. Association of patisiran, an RNA interference therapeutic, with regional left ventricular myocardial strain in hereditary transthyretin amyloidosis: the APOLLO study. JAMA Cardiol. 2019;4:466. doi:10.1001/jamacardio.2019.0849.
   PubMed Web of Science ®Google Scholar
• Dolobid (diflunisal) [package insert]. Whitehouse Station, NJ: Merck & Co., Inc; 2007.
   Google Scholar
• Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310:2658–2667. doi:10.1001/jama.2013.283815.
   PubMed Web of Science ®Google Scholar
• Rosenblum H, Castano A, Alvarez J, Goldsmith J, Helmke S, Maurer MS. TTR (Transthyretin) stabilizers are associated with improved survival in patients with TTR cardiac amyloidosis. Circulation Heart Fail. 2018;11:e004769. doi:10.1161/CIRCHEARTFAILURE.117.004769.
   PubMed Web of Science ®Google Scholar
• Eidos Therapeutics. Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Cardiomyopathy. ClinicalTrials.gov Identifier: NCT03860935. 2019. https://clinicaltrials.gov/ct2/show/NCT03860935.
   Google Scholar
• Judge DP, Falk RH, Maurer MS, et al. Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2019;74:285–295. doi:10.1016/j.jacc.2019.03.012.
   PubMed Web of Science ®Google Scholar
• Ionis Pharmaceuticals, Inc. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONTTR-LRx in Healthy Volunteers and Patients with Hereditary Transthyretin-Mediated Amyloidosis. ClinicalTrials.gov Identifier: NCT03728634. 2018. https://clinicaltrials.gov/ct2/show/NCT03728634.
   Google Scholar
• Alnylam Pharmaceuticals. HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis). ClinicalTrials.gov Identifier: NCT03759379. 2021. https://clinicaltrials.gov/ct2/show/NCT03759379.
   Google Scholar
• Prothena Biosciences Limited. A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis. ClinicalTrials.gov Identifier: NCT03336580. 2021. https://clinicaltrials.gov/ct2/show/NCT03336580.
   Google Scholar
• Palladini, G, IRCCS Policlinico S. Matteo. A Study of Doxycycline and Tauroursodeoxycholic Acid (Doxy/TUDCA) Plus Standard Supportive Therapy Versus Standard Supportive Therapy Alone in Cardiac Amyloidosis Caused by Transthyretin. ClinicalTrials.gov Identifier: NCT03481972. 2021. https://clinicaltrials.gov/ct2/show/NCT03481972.
   Google Scholar
• Karlstedt E, Jimenez-Zepeda V, Howlett JG, White JA, Fine NM. Clinical experience with the use of doxycycline and ursodeoxycholic acid for the treatment of transthyretin cardiac amyloidosis. J Card Fail. 2019;25:147–153. doi:10.1016/j.cardfail.2019.01.006.
   Web of Science ®Google Scholar
• Witteles RM. Doxycycline and ursodiol for ATTR amyloidosis: not ready for prime time. J Card Fail. 2019;25:154–155. doi:10.1016/j.cardfail.2019.01.014.
   Web of Science ®Google Scholar